Linerixibat - GSK
Alternative Names: GSK 2330672; GSK 672; LynavoyLatest Information Update: 24 Mar 2026
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antihyperglycaemics; Antipruritics; Benzene derivatives; Carboxylic acids; Ethers; Small molecules; Thiazepines
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Yes - Pruritus
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Pruritus
- Discontinued Cholestasis; Type 2 diabetes mellitus
Most Recent Events
- 24 Mar 2026 Discontinued - Phase-I for Cholestasis (In volunteers) in Japan (PO), before March 2026 (GSK pipeline, March 2026)
- 24 Mar 2026 Discontinued - Phase-I for Cholestasis (In volunteers) in United Kingdom (IV), before March 2026 (GSK pipeline, March 2026)
- 24 Mar 2026 Discontinued - Phase-I for Cholestasis (In volunteers) in United Kingdom (PO), before March 2026 (GSK pipeline, March 2026)